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KRAS is a proto-oncogene which was first identified in Kirsten rat 
sarcoma virus.  The normal KRAS protein performs an essential function in 
normal tissue signaling and a mutation of a KRAS gene is an essential step 
in the development of many cancers.  Q-Clamp® KRAS codon specific 
mutation test is an in vitro real-time qualitative PCR assay for the detection 
of mutations in the targeted regions and KRAS mutation often serves as a 
useful marker in drug response.  The Q-Clamp® KRAS codon specific 
mutation test experiment was performed using cell-free extracted DNA 
(cfDNA) instead of FFPE extracted DNA. The results of the experiment 
showed a clear difference in the Ct’s between the mutant and internal 
control.  Since the delta Ct’s can be discriminated, the assay showed a 
positive feasibility of using a cfDNA in the Q-Clamp® KRAS codon specific 
mutation test. 
   
Objectives  
1. Describe KRAS, the specific codons it mutates, and its pathways.   
2. Describe the mechanics of the assay, how it works, and its intended use.  
3. Describe cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). 








This review is based on published, peer-reviewed literature; available 
information from medical organizations (eg, National Comprehensive Cancer 
Network, American Society of Clinical Oncology, College of American 
Pathologists); and information from clinical laboratories 
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A. KRAS  
KRAS is a proto-oncogene which was first identified in Kirsten rat 
sarcoma virus (Tsuchida, et al., 1982).  The KRAS gene provides instructions 
for making a protein called K-Ras that is part of a signaling pathway known as 
the RAS/MAPK pathway (http://www.diacarta.com/products/gene-mutation-
detection-kits-2/kras-mutation-test/).   The normal KRAS protein performs an 
essential function in normal tissue signaling and the mutation of a KRAS gene 
is an essential step in the development of many cancers, according to 
Kranenburg (2005), including colorectal, lung, thyroid and pancreatic cancers, 
and colangiocarcinomas.  The KRAS gene is in the Ras family of oncogenes, 
which also includes two other genes: HRAS and NRAS.  These proteins play 
important roles in cell division, cell differentiation, and the self-destruction of 
cells (apoptosis) (http://www.diacarta.com/products/gene-mutation-detection-
kits-2/kras-mutation-test/).  
The codons where KRAS clinically relevant mutations are usually 
observed are within codons 12 and 13 of exon 2, codons 59 and 61 in exon 3, 
and codons 117 and 146 in exon 4.  KRAS mutation will lead to abnormal 
growth signaling and the alterations in cell growth and division may trigger 
cancer development because of excessive cell growth and division due to 
excessive signaling.  A KRAS mutation can also serve as a useful prognostic 
marker response to tyrosine kinase inhibitors and in certain colorectal cancer 




B. MAP Kinase (Mitogen-Activated Protein Kinase) Pathway 
The RAS proteins such as KRAS, HRAS, and NRAS are small 
guanosine triphosphatases (GTPases) associated with a number of signal 
transduction pathways involved in cell cycle progression, cell motility, 
apoptosis, senescence and other vital functions.   
Numerous cell surface molecules activate RAS proteins, which in turn 
activate MAPK cascades, including RAF, MEK and ERK, a major effector 
pathway of RAS with a well-described role in cancer.  Signaling events 
initiated by RAS that are transduced through RAF, MEK, and ERK 1 & 2 are 
transmitted to the nucleus where they regulate transcription factors to 
modulate gene expression required for cellular proliferation, growth 
differentiation, transformation, and survival.  Dysregulation of key mediators 
of the MAPK pathway have been implicated as drivers of cancer 
development.  RAS mutations have been identified in both hematologic and 
solid tumors.  KRAS is frequently mutated in cancer of the colon and lungs.   
MAPK pathway activation begins at the cell membrane, where small 
GTPases and various protein kinases phosphorylate and activate MAPKKKs.  
Subsequently, MAPKKKs directly phosphorylate MAPKKs which, once 
activated, phosphorylate MAPKs.  Activated MAPKs interact with and 
phosphorylate other cytoplasmic substrates and ultimately modulate 
transcription factors that drive gene expression.  This is turn results in various 
biological responses like osmotic shock, cell cycle progression, or induction of 




Figure 1 presents the KRAS mutation wherein the transmembrane 
receptor which is activated by ligand binding triggers the intracellular signaling 
cascade resulting in the impact of the gene expression which leads to the cell 
proliferation that eventually dysregulate the pathway, thus leads to tumor 
progression.  
 
Figure 1.  KRAS Mutation. A) In a cell where no mutation is present, the 
transduction/signaling pathway is shut off.  B) When growth factors (shown in 
green) are present and bind to their corresponding receptor, KRAS protein is 
activated; downstream proteins carry the signal to the nucleus and activate 
gene transcription. C) In a cell where KRAS is mutated, the transduction 





C. Q-Clamp® KRAS Codon Specific Mutation Test 
The Q-Clamp® KRAS Codon Specific Mutation Test (DiaCarta, Inc, 
Richmond,CA) is a CE marked in vitro diagnostic real-time qualitative PCR 
test that will detect genetic mutations in codons 12 and 13 in exon 2, codons 
59 and 61 in exon 3, and codons 117 and 146 in exon 4 in the human KRAS 
gene.  According to the assay manual, sample sources for the test can be 
from extracted and purified DNA from formalin fixed paraffin embedded 
(FFPE), plasma, cells, or tissue.  The version of the assay (not an FDA-
approved assay) was developed with FFPE extracted DNA and reference 
standards.  Because the mutation sensitivity is at 1% or below, it has the 
capability of being used for plasma samples and cfDNA.  The test detects the 
presence or absence of KRAS mutations in the targeted regions but does not 
specify the exact nature of the mutation (http://www.diacarta.com/products/ 
gene-mutation-detection-kits-2/kras-mutation-test).     
The validated instruments and product specification are shown in  
Table 1. 
Specification QClamp KRAS Codon Specific Mutation Test 
Intended Use  
For In Vitro Diagnostic Use (CE/IVD) or For Research 
Use  
Sample Type  Extracted (DNA) at 2.5ng/µL concentration 
Pack Size  10 Samples, 30 Samples, and 60 Samples  
Validated 
Instruments  
Roche LC 96, LC 480 II, Bio-Rad CFX384 and ABI 
Quant Studio 5  
Detection Channel  FAM; HEX  
Turnaround Time  <4 hours  
Stability  Stable for 12 months at -25°C to -15°C 






D. Q-Clamp® KRAS Codon Specific Mutation Test Principle 
The Q-Clamp® KRAS Codon Specific Mutation Test is based on 
xenonucleic acid (XNA) mediated Polymerase Chain Reaction (PCR) 
clamping technology.  XNA is a synthetic DNA analog in which the 
phosphodiester backbone has been replaced by a repeat formed by units of 
(2-aminoethyl)-glycine.  If there is a complete match of DNA target sequence, 
the XNA will hybridize tightly to that matching complementary DNA target 
sequences and this binding will block the elongation of the DNA strand by 
DNA polymerase, hence preventing its amplification.  When there is a 
mismatch in the target site, in the case of a mutation, the XNA will not be able 
to hybridize tightly to the target sequence making the XNA:DNA duplex 
unstable.  If the XNA:DNA duplex is unstable, the DNA polymerase will be 
able to elongate the DNA strand.  Thus, the addition of XNA, with a sequence 
completely matching the wild-type of DNA sequence, in a PCR reaction, will 
selectively prevent the wild type DNA from being amplified allowing the 
mutated DNA to amplify.  Furthermore, the DNA polymerase will not 
recognize XNA oligomers and therefore it cannot be used as primers in the 
following real-time PCR reactions (http://www.kleegmbh.ch/diagnostics/ 
mutation-detection.html).  
Figure 2 is the schematic representation of the molecular approach 
used for mutation and translocation detection. Samples are amplified in 
reactions with and without the XNA clamp. The sample is considered positive 
when the threshold cycle (CT) difference in reactions with and without the 




Figure 2. Q-Clamp® PCR Principle Diagram.  To reduce the wild-type 
background and improve sensitivity, a molecular clamp has been designed to 
hybridize selectively to wild-type template DNA and block its amplification.  This 
molecular clamp consists of a synthetic, sequence-specific Xeno-nucleic acid 
(XNA) probe. In the presence of a mutation such as a single nucleotide 
polymorphism (SNP) gene deletion, insertion, or rearrangement in the region of 
the XNA probe sequence, the XNA probe molecule melts off the mutant template 
DNA during the PCR cycling process, and only mutant templates are amplified 
efficiently (Q-Clamp® Kras codon specific mutation test instruction manual). 
 
E. Cell-Free DNA  
Cell-free DNA or cfDNA refers to all non-encapsulated DNA in the blood 
stream. A portion of that cell-free DNA originates from a tumor clone and is 
called circulating tumor DNA or ctDNA.  cfDNA are nucleic acid fragments 
that enter the bloodstream during apoptosis or necrosis. Normally, these 
fragments are cleaned up by macrophages, but  the overproduction of cells in 
cancer leaves more of the cfDNA behind.  These fragments average around 
170 base pairs in length, have a half-life of about two hours and are present 
in both early and late stage disease in many common tumors including non-




blog/behindthebench/what-is-cell-free-dna-cfdna-seq-it-out-19). ctDNA should 
not be confused with cell-free DNA (cfDNA), a broader term which describes 
DNA that is freely circulating in the bloodstream, but is not necessarily of 
tumor origin.  ctDNA originates directly from the tumor or from circulating 
tumor cells (CTCs), which describes viable, intact tumor cells that shed from 
primary tumors and enter the bloodstream or lymphatic system.  In healthy 
tissue, infiltrating phagocytes are responsible for clearance of apoptotic or 
necrotic cellular debris, which includes cfDNA. Levels of cfDNA in healthy 
patients is only present at low levels but higher levels of ctDNA in cancer 
patients can be detected.  This possibly occurs due to inefficient immune cell 
infiltration to tumor sites, which reduces effective clearance of ctDNA from the 
















II. MATERIALS AND METHODS  
Materials: 
- KRAS Q-Clamp® Kit 
- cfDNA derived from human plasma  
- Horizon Diagnostics cfDNA Reference Standard (Horizon Discovery, 
www.horizondiscovery.com) 
- Thermal Cyclers (eBioRad CFX 384) 
- 384-well plate 
 
Purpose  
This experiment was performed to test if the limit of detection could go 
low enough using cfDNA in an assay kit designed and optimized using FFPE 
extracted DNA and genomic DNA references. 
 
Q-Clamp®  Workflow:  
The assay workflow consists of four (4) major steps:  
1. DNA isolation;  
2. Set up qPCR;  
3. Enter amplification parameters; and 







A. DNA Isolation 
Acquisition of cfDNA or ctDNA typically requires collection of 
approximately 3 ml of blood into EDTA-coated tubes. The plasma fraction of 
blood is separated through centrifugation. Plasma is then processed again by 
another centrifugation to remove residual intact blood cells. The supernatant 
is used for DNA extraction which can be performed using commercially 
available kits (https://en.wikipedia.org/wiki/circulating_tumor_DNA). 
 
B. Set Up qPCR 
Samples used are Reference Standard (mutant DNA), Diluent (wild 
type DNA); both are cell-free DNA. 
The assay was set up by serially diluting 5 ng (2uL) of the 5% mutant 
cfDNA standard reference with 5 ng of  the wild type cfDNA (2uL) at 0.5, 0.25, 
0.125 and 0.0625 dilutions. Two µL of this mixture from these dilutions was 
added to the reaction plate. Each sample and control  was run in duplicate. 
The PCR reactions are set up in a total volume of 10 μL/reaction as 
shown in Table 2. 
Components Volume/Reaction 
2x PCR Master mix  5µL  
Primer / Probe mix  1µL 
XNA  1µL 
Nuclease Free water   1µL 
DNA Template (Samples and 
Controls)  
2µL  to be added last in the plate  
Total Volume  10µL 





A set of positive controls must also be run with each reaction mix, 
every time the assay is run. The Positive Control contains one mutant 
template for each reaction mix.  Negative Controls use wild-type DNA as the 
template.  Wild type DNA should have no mutations.  A set of no template 
control (tube NTC) is run with each reaction mix every time the assay is run. 
Nuclease-Free Water is used in the place of template.  The NTC serves as a 
negative control and assesses potential contamination during assay set-up.    
 
C. Enter Amplification Parameters 
Eight uL of the mixture (PCR master mix, PPM, XNA, and water) was 
transferred to each well in a 384-well plate using a multichannel pipette as 
reflected in Table 3. 





samples)   
   
0.5 0.25 0.125 0.0625 
A C12 PC CC NTC S S S S 
B C12 PC CC NTC S S S S 
C         
D C13 PC CC NTC S S S S 
E C13 PC CC NTC S S S S 
F         
G C59 PC CC NTC S S S S 
H C59 PC CC NTC S S S S 
I         
J C61 PC CC NTC S S S S 
K C61 PC CC NTC S S S S 
L         
M C146 PC CC NTC S S S S 
N C146 PC CC NTC S S S S 
Table 3.  Plate Map BioRad CFX 384.  PC – Positive Control; CC – Clamping      





D. Data Analysis 
Each sample tube is a multiplex PCR consisting of amplification 
primers and probes for an internal amplification control (B-actin gene) and the 
specific KRAS codon. During PCR, the accumulating amplicons for both the  
Internal control gene (B-actin) and the KRAS codon are measured by means 
of fluorescent tagged qPCR probes (HEX for B-actin and FAM for KRAS). 
Analysis is performed using both FAM and HEX channel readings.  
The Ct values from these files is used to evaluate the presence or absence of 
mutations using the Q-Clamp® KRAS codon specific mutation test user 
manual.   
A cycle threshold (Ct) value for each analyzed sample is generated by 
the PCR instrument.  The Ct is the cycle number at which a signal is detected 
above the set threshold for fluorescence.  The higher the cycle number at 
which signal is detected, the weaker is the PCR reaction.  On the other hand, 
the lower the cycle number at which signal is detected, the stronger the PCR 
reaction it represents.   
 
Controls Analysis:  
Wild type DNA is used as the template for the mutation negative 
controls (Clamping Controls).  This wild type DNA does not contain the 
targeted mutations, so the XNA probes will strongly bind to it inhibiting the 
KRAS amplification. The internal control should amplify to specified amounts 
though. This will monitor the performance of the primers, polymerase and 
sample DNA quality and quantity.  
 
12 
The positive control template contains mutations, so the XNA probe 
will not bind to the template allowing the KRAS amplification.  Positive     
controls must show the appropriate value in both HEX and FAM channels to 
make the run valid.  
The no-template controls (NTC) should have no amplification for any of 
the reactions.  Cycle threshold (Ct) should be undetermined.    
 
Mutation Analysis:  
The presence or absence of a mutation is determined by the difference 
in the Ct values in the B-actin (internal control) and the KRAS (mutation) 
amplifications reactions.  The difference in Ct value between the Mutation 
assay and the Internal Control assay (HEX) as follows:  














III. RESULTS  
Codon Channel PC NC NTC 
Dilution 
0.5 0.25 0.125 0.625 
C12 FAM 32.42 42.94 45 34.08 35.88 39.74 36.25 
HEX 26.45 26.80 45 30.51 30.78 30.56 30.60 
C13 FAM 32.83 42.38 45 34.94 37.83 36.06 41.66 
HEX 26.75 26.38 45 30.68 31.07 30.34 30.43 
C59 FAM 34.29 39.79 45 35.82 35.47 35.24 36.46 
HEX 26.80 26.52 45 30.58 31.10 30.85 30.45 
C61 FAM 36.83 43.01 45 * 38.81 * 40.87 
HEX 26.25 26.06 45 32.02 30.59 * 30.36 
C146 FAM 35.96 43.08 45 44.95 38.36 38.22 * 
HEX 26.53 26.17 45 30.29 31.01 30.03 * 
Table 4.  Results for Run in BioRad CFX 384 (Average Cts of FAM and 
HEX).  PC = Positive Control; NC = Clamping Control - Negative Mutation 
Control; NTC = No Template Control;   = No Amplification 
  
Codon PC NC NTC 0.5 0.25 0.125 0.0625 
C12 5.975 16.775 0 3.565 5.095 9.185 5.64 
C13 6.08 15.99 0 4.26 6.76 5.72 11.23 
C59 7.49 13.27 0 5.24 4.365 4.39 6.01 
C61 10.58 16.95 0       * 8.23       * 10.51 
C146 9.425 16.9 0 14.66 7.35 8.19      * 
Table 5.  Data Analysis for BioRad CFX 384 (Average ∆ CT). PC = Positive 
Control; NC = Clamping Control – Negative Mutation Control; NTC = No 












Codon (Positive) Control  
Acceptable Values 
Clamping Control (Negative) 
Acceptable Values 
C12 ∆ CT ≤ 7 ∆ CT > 10.5 
C13 ∆ CT ≤ 7 ∆ CT > 10.5 
C59 ∆ CT ≤ 8.4 ∆ CT > 10.5 
C61 ∆ CT ≤ 11 ∆ CT > 13.5 
C146 ∆ CT ≤ 11 ∆ CT > 13 
Table 6. Acceptable Values for Positive Controls and Clamping Controls 
for BioRad CFX 384.     
 
 KRAS Target Codon 
Call C12 C13 C59 C61 C146 
Positive  ≤ 10.5 ≤ 10.7 ≤ 10.6 ≤ 13.65 ≤ 13 
Negative  >10.5 >10.7 >10.6 >13.65 >13 
Table 7.  Scoring Mutational Status for BioRad CFX 384.  
 
 Copy Number of Mutant DNA (5ng input DNA) 




38 19 9 5 






IV.  CONCLUSION   
In this experiment, a cell-free DNA reference standard containing all 
the mutations diluted into cell-free DNA was used as the sample instead of 
FFPE extracted genomic DNA. The experiment went well as evidenced by the 
results of the control values passing the criteria stated in the instruction 
manual. The average CTs of the controls (Positive Control, Negative Control 
and the No-template Control) of both the FAM and HEX channels of all the 
codons tested were all within the specified limits in the instruction manual. 
As for scoring the mutational status of the codons tested, codon C12 is 
positive for mutation at 0.5, 0.25, 0.125 and 0.0625 dilutions which means 
that detection is observed up to 0.3%. Codon C13 is positive for mutation at 
0.5, 0.25 and 0.125 dilutions which indicates that the limit of detection with 
this particular codon is at 0.6%. Codon C59 is positive for mutation at 0.5, 
0.25, 0.125 and 0.0625 dilutions so detection is up to 0.3% and with codon 
C61  the assay was able to detect mutation at 0.25 and 0.0625 dilutions. 
Codon C146 had mutation detected at 1.25 and 0.625 dilutions. 
With these results, it is observed that three of the five codons (C12, 
C59 and C61) tested can be detected up to 0.3%. The limit of detection for 
codon C13 is at 0.6% and C146 at 0.6%. There was no attempt to proceed 
further dilutions to see how far can possibly detect mutation for C12, C59 and 
C61 because of unavailability of resources. 
The corresponding copy number of mutant DNA is approximately 38 
copies for the 2.5% mutation, 19 copies for the 1.25% mutation, 9 copies for 
the 0.6% mutation  and 5 copies for the 0.3% mutation. 
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The internal control values for the samples were higher than expected 
which indicates not enough amplifiable DNA was in the reactions or there 
may have been some inhibition in the sample resulting to sub-optimal 
amplification. Again because of limited materials, no further testing was done. 
Future work would include repeating this experiment to see if there was a 
problem with just this run or with cfDNA in general, looking at different cell-
free extracts with reference standards in them and when optimized, looking at 
different clinical samples.  Based on the Ct value specification for the internal 
control, for clinical samples in a validated test, the mutation scoring would 
have not proceeded.  However, since a clear difference could be 
distinguished in the delta Ct’s between mutation positive (the dilution series) 
and mutation negative (clamping control/negative control) reactions, it 
provides the basis for moving forward with continued experiments to further 
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